Insider Selling: Incyte (NASDAQ:INCY) Insider Sells 2,774 Shares of Stock

Incyte Corporation (NASDAQ:INCY) insider Thomas Tray sold 2,774 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $100.00, for a total transaction of $277,400.00. Following the transaction, the insider owned 22,973 shares of the company’s stock, valued at $2,297,300. This represents a 10.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Thomas Tray also recently made the following trade(s):

• On Thursday, December 18th, Thomas Tray sold 600 shares of Incyte stock. The shares were sold at an average price of $98.25, for a total transaction of $58,950.00.

Incyte Price Performance

Shares of Incyte stock traded down $1.98 on Monday, hitting $100.71. 1,932,285 shares of the company were exchanged, compared to its average volume of 2,207,190. Incyte Corporation has a 1-year low of $53.56 and a 1-year high of $109.28. The company has a quick ratio of 3.13, a current ratio of 3.20 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $19.77 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 0.70 and a beta of 0.81. The company has a 50-day moving average price of $98.53 and a 200 day moving average price of $85.09.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.26 billion. During the same period in the prior year, the business earned $1.07 EPS. The firm’s quarterly revenue was up 20.0% on a year-over-year basis. As a group, sell-side analysts predict that Incyte Corporation will post 4.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of INCY. Raymond James Financial Inc. increased its stake in Incyte by 33.0% in the first quarter. Raymond James Financial Inc. now owns 69,762 shares of the biopharmaceutical company’s stock valued at $4,224,000 after purchasing an additional 17,313 shares during the last quarter. Northern Trust Corp boosted its position in shares of Incyte by 0.6% in the first quarter. Northern Trust Corp now owns 1,706,402 shares of the biopharmaceutical company’s stock worth $103,323,000 after acquiring an additional 10,279 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of Incyte by 11,900.0% in the 1st quarter. Quantbot Technologies LP now owns 9,120 shares of the biopharmaceutical company’s stock valued at $552,000 after purchasing an additional 9,044 shares during the last quarter. Credit Agricole S A increased its holdings in shares of Incyte by 62.7% during the 1st quarter. Credit Agricole S A now owns 10,987 shares of the biopharmaceutical company’s stock worth $665,000 after buying an additional 4,234 shares during the last quarter. Finally, Norinchukin Bank The raised its position in shares of Incyte by 15.2% in the 1st quarter. Norinchukin Bank The now owns 8,322 shares of the biopharmaceutical company’s stock worth $504,000 after buying an additional 1,100 shares during the period. 96.97% of the stock is owned by hedge funds and other institutional investors.

Key Stores Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Japan regulatory wins expand commercial footprint — Japan approved Zynyz (retifanlimab) for first‑line advanced anal cancer and approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma. These approvals support additional revenue and market expansion in a major market. Article Title Article Title
• Neutral Sentiment: Momentum/analyst note: a Zacks piece flagged a recent ~5.5% rally and above‑average volume but warned that recent estimate revisions may limit near‑term upside — supportive of interest but not a clear buy signal on its own. Article Title
• Negative Sentiment: Insider selling: EVP and other insiders reported large sales — Incyte EVP sold about $5.25M of stock, and director/officer Thomas Tray disclosed sales totaling 3,374 shares across Dec. 18–19 (~$98–$100 per share). Large, concentrated insider sales can signal near‑term selling pressure or raise governance questions. Article Title SEC Filing

Analysts Set New Price Targets

A number of research firms recently weighed in on INCY. Barclays increased their price objective on shares of Incyte from $101.00 to $115.00 and gave the stock an “overweight” rating in a research report on Monday, November 24th. Bank of America boosted their target price on shares of Incyte from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, September 4th. Oppenheimer cut Incyte from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Royal Bank Of Canada raised their target price on Incyte from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Truist Financial restated a “hold” rating and set a $93.00 target price (up previously from $79.00) on shares of Incyte in a research note on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Incyte presently has a consensus rating of “Hold” and an average price target of $99.07.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.